Literature DB >> 3818430

Chemotherapy of lymphoma in 75 cats.

K A Jeglum, A Whereat, K Young.   

Abstract

Seventy-five cats with lymphoma were treated with combination sequential chemotherapy consisting of vincristine, cyclophosphamide, and methotrexate. Thirty-nine cats had mediastinal, 16 had multicentric, 14 had alimentary, and 6 had renal lymphoma. The median survival time of the 75 cats was 8 weeks, with a mean of 32 weeks. Sixty-two cats had follow-up evaluation until death or cure and had a median survival time of 7 weeks, with a mean of 37 weeks. Of the 62 cats, 32 (52%) attained complete remission, with a median remission duration of 16 weeks and a mean of 46 weeks. The addition of prednisolone and/or L-asparaginase to the protocol did not improve the results. Sixteen cats with multicentric lymphoma had the longest survival times (median, 18 months) and remission durations (median, 25 months). Prognostic factors were evaluated in each anatomic form of lymphoma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3818430

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  3 in total

1.  Treatment of feline intermediate- to high-grade lymphoma with a modified university of Wisconsin-Madison protocol: 119 cases (2004-2012).

Authors:  S A Collette; S D Allstadt; E M Chon; W Vernau; A N Smith; L D Garrett; K Choy; R B Rebhun; C O Rodriguez; K A Skorupski
Journal:  Vet Comp Oncol       Date:  2015-06-25       Impact factor: 2.613

2.  Hypersensitivity reactions associated with L-asparaginase administration in 142 dogs and 68 cats with lymphoid malignancies: 2007-2012.

Authors:  Mary Kay Blake; Brittany J Carr; Glenna E Mauldin
Journal:  Can Vet J       Date:  2016-02       Impact factor: 1.008

3.  Prognostic analyses on anatomical and morphological classification of feline lymphoma.

Authors:  Hirofumi Sato; Yasuhito Fujino; Junko Chino; Masashi Takahashi; Kenjiro Fukushima; Yuko Goto-Koshino; Kazuyuki Uchida; Koichi Ohno; Hajime Tsujimoto
Journal:  J Vet Med Sci       Date:  2014-02-10       Impact factor: 1.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.